Glaucoma Associated with Aniridia

Key Points at a Glance

Congenital aniridia is an iris defect caused by loss-of-function mutations in the PAX6 gene (11p13), with an incidence of 1 in 50,000 to 100,000 people.
Glaucoma develops as an acquired complication in 50–75% of aniridia cases, rarely in infancy and progressively manifesting after adolescence¹⁾.
The main etiology is impaired aqueous humor outflow due to angle dysgenesis, with both open-angle and angle-closure types present.
Treatment begins with medication; if insufficient, it progresses stepwise to outflow reconstruction, filtering surgery or tube shunt surgery, and cyclophotocoagulation²⁾.
Be aware of WAGR syndrome (Wilms tumor, aniridia, genitourinary abnormalities, intellectual disability); in sporadic cases, abdominal ultrasound screening is recommended until age 6.
Visual prognosis is generally poor, often around 0.1, with foveal hypoplasia, glaucoma, and keratopathy being the main factors for vision loss.
Lifelong regular intraocular pressure monitoring and multidisciplinary systemic management are essential.

1. Glaucoma Associated with Aniridia

Congenital aniridia is a rare disease characterized by complete or partial absence of the iris. Its prevalence is 1 in 64,000 to 96,000 people, and it was classified as a designated intractable disease in Japan in 2017¹⁾.

The cause is a loss-of-function mutation in the PAX6 gene on chromosome 11p13. PAX6 is a master control gene for eye development, and haploinsufficiency leads to the disease. Biallelic abnormalities are embryonically lethal¹⁾. Inheritance is autosomal dominant in two-thirds of cases, and sporadic in the remaining one-third. 60–90% are bilateral, with a slight male predominance.

Glaucoma is considered an acquired complication of aniridia, occurring in 50–75% of cases due to angle dysgenesis¹⁾. Onset in infancy is rare, and it progressively develops after adolescence. Glaucoma associated with aniridia is classified as a secondary type of childhood glaucoma. Management follows treatment principles for primary congenital glaucoma (PCG), but the unique angle dysgenesis in aniridia requires special considerations in treatment strategy.

Aniridia is a pan-ocular disease accompanied by various ocular and systemic complications besides glaucoma, with high rates of macular hypoplasia, aniridia-associated keratopathy (AAK), cataracts, and nystagmus. Sporadic cases may present with WAGR syndrome due to deletion of the WT1 gene adjacent to the PAX6 gene, requiring attention to the complication of Wilms tumor (nephroblastoma).

Q If diagnosed with aniridia, will I definitely develop glaucoma?

Glaucoma occurs in 50–75% of cases, but not all patients develop it. Onset in infancy is rare, and progressive intraocular pressure elevation often becomes apparent after adolescence, so lifelong regular intraocular pressure monitoring is important.

2. Main Symptoms and Clinical Findings

Subjective Symptoms

The main complaint in aniridia is often horizontal nystagmus, which appears early after birth due to associated macular hypoplasia. Because the iris is missing, the amount of light entering the eye cannot be regulated, leading to severe photophobia (glare). Poor fixation is also observed, and the condition is often detected relatively early in life.

Symptoms related to glaucoma are as follows:

Symptoms due to elevated intraocular pressure: Often progresses asymptomatically. Since open-angle type is common, subjective pain is rare.
Visual field defects and vision loss: In advanced cases, visual field narrowing or vision loss may be discovered in adulthood.
Visual prognosis: Generally poor, often around 0.1. Macular hypoplasia is the major factor for vision loss.

Clinical Findings (Findings Confirmed by Physician Examination)

Slit-lamp examination reveals varying degrees of iris dysplasia, from partial iris atrophy to complete iris absence¹⁾. In cases of severe absence, the lens equator and zonules of Zinn may be visible.

Glaucoma-related findings:

Elevated intraocular pressure: High intraocular pressure exceeding 21 mmHg. Corneal thickness may differ from normal (tendency to be thicker), making estimation of true intraocular pressure difficult.
Optic disc findings: Increased cup-to-disc ratio (C/D ratio), thinning of the neuroretinal rim. In infants, a C/D ratio of 0.3 or more suggests glaucoma.
Angle findings: Abnormalities in the iris root are observed. The iris stroma extends anteriorly over the trabecular meshwork, progressively covering the angle.
Corneal findings: Haab striae (breaks in the corneal endothelium), corneal edema due to high intraocular pressure. In newborns, a corneal diameter of 11 mm or more is abnormal.

Main ocular complications:

Macular hypoplasia

Frequency: Occurs in nearly all cases.

Impact on visual prognosis: The most significant factor for vision loss. Presents with absence of the foveal pit and abnormal macular vascularity.

Corneal disease (AAK)

Frequency: Develops progressively.

Characteristics: Conjunctival tissue invades the cornea due to limbal stem cell deficiency. Leads to pannus formation and corneal opacity.

Cataract

Frequency: Occurs in about 80% of cases¹⁾.

Characteristics: Develops in 50–85% of patients by age 20. Surgery is challenging due to fragile zonules of Zinn.

Nystagmus

Frequency: Seen in all cases.

Characteristics: Primarily horizontal nystagmus. Often a major complaint in early infancy. Affects visual development.

Association with long-term prognosis of glaucoma:

In a case series of 306 patients, no patient with glaucoma had visual acuity exceeding 20/60 (0.33)¹⁵⁾. In another study of 30 patients, 10 (30%) had glaucoma, which was the main cause of visual impairment. Among them, 2 patients (6%) became blind¹⁶⁾. Visual field and optic nerve damage due to glaucoma is irreversible, and early detection and appropriate intraocular pressure management are directly linked to preserving visual function.

Extraocular findings include Wilms tumor, genitourinary abnormalities, and intellectual developmental delay in WAGR syndrome (11p13 deletion syndrome). PAX6 is also expressed in the central nervous system, pancreatic islets of Langerhans, and olfactory epithelium, and complications such as agenesis of the corpus callosum, epilepsy, higher brain dysfunction, anosmia, and glucose intolerance have been reported¹⁾.

3. Causes and Risk Factors

PAX6 Gene and Aniridia

PAX6 is expressed from the early eye and is a master control gene for eye development, regulating various transcription factors. Abnormalities in PAX6 cause congenital anomalies throughout the eye (aniridia, Peters anomaly, macular hypoplasia, optic nerve hypoplasia, etc.).

The types of genetic mutations and associated diseases are shown below.

Gene	Chromosome	Associated Disease
PAX6	11p13	Aniridia, macular hypoplasia, Peters anomaly
WT1	11p13 (adjacent to PAX6)	Wilms tumor
PITX2	4q25	Axenfeld-Rieger syndrome type 1
FOXC1	6p25	Axenfeld-Rieger syndrome type 3

PAX6 mutations are often premature truncated codon (PTC) types such as nonsense and frameshift mutations, and missense mutations have also been reported¹⁾. Sequencing detects some mutation in nearly 85% of isolated aniridia cases²⁾.

In a large registry study, genetic diagnosis was obtained in 56.5% of glaucoma associated with non-acquired ocular developmental anomalies, and PAX6 has been shown to be one of the major causative genes¹⁰⁾.

WAGR syndrome and Wilms tumor

PAX6 and WT1 (the causative gene for Wilms tumor) are adjacent on 11p13, and chromosomal deletions involving both result in aniridia complicated by Wilms tumor (WAGR syndrome: Wilms tumor, Aniridia, Genitourinary abnormalities, mental Retardation).

Approximately 1/3 of aniridia cases are part of WAGR syndrome²⁾
About 30% of sporadic cases develop Wilms tumor by age 5
Congenital aniridia is found in 1.4% of Wilms tumor patients

Risk factors for glaucoma development

Degree of angle dysgenesis: The more the iris stroma extends anteriorly onto the trabecular meshwork, the higher the risk
Age: Progressively develops after adolescence with growth. Intraocular pressure monitoring from childhood is essential.
History of cataract surgery: There is a risk of increased intraocular pressure or worsening of glaucoma after surgery²⁾.

Q If WAGR syndrome is suspected, what tests should be performed?

Chromosomal microarray (CMA) or FISH testing is recommended to detect deletions in the 11p13 region, including PAX6 and the adjacent WT1 gene. If a deletion of the WT1 gene is confirmed, the risk of Wilms tumor is high, so regular abdominal ultrasound examinations are required until age 6. Testing should ideally be performed under genetic counseling²⁾.

4. Diagnosis and Testing Methods

Diagnosis of Aniridia

Clinical diagnosis is easy by confirming iris defects with slit-lamp microscopy. The diagnostic criteria established by the Ministry of Health, Labour and Welfare research group are classified into the following categories¹⁾.

Definite: A symptom (either binocular visual impairment or photophobia) + B1 (iris dysplasia) + E (PAX6 gene mutation or 11p13 deletion) + C (exclusion of differential diagnoses)
Probable: (1) A + B1 + F (family history), (2) A + B1 + B2 (foveal hypoplasia), or (3) A + B1 + B3 (corneal disease), with C excluded
Possible: A + B1 met, but C cannot be completely excluded

Severity classification is based on corrected visual acuity and visual field constriction¹⁾.

Severity	Criteria
Grade I	Unilateral involvement, fellow eye healthy
Grade II	Bilateral involvement, best corrected visual acuity in the better eye ≥ 0.3
Grade III	Bilateral involvement, best corrected visual acuity in the better eye ≥ 0.1 and < 0.3
Grade IV	Bilateral involvement, best corrected visual acuity in the better eye < 0.1

For grades I–III, if accompanied by visual field narrowing due to secondary glaucoma, the severity shifts up by one grade¹⁾. Grade III or higher qualifies for medical expense subsidies for designated intractable diseases.

Diagnosis of Glaucoma

The diagnostic criteria for pediatric glaucoma are as follows: glaucoma is diagnosed when two or more of the following items are met.

Intraocular pressure > 21 mmHg (including under general anesthesia)
Progression of cup-to-disc ratio increase, asymmetry ≥ 0.2, rim thinning
Corneal findings: Haab striae, corneal diameter ≥ 11 mm in newborns, ≥ 12 mm in infants under 1 year
Progression of myopia due to axial elongation
Reproducibility of glaucomatous visual field defects

In aniridia, corneal thickness may differ from normal (tendency to thicken, or thinning in aphakic eyes), requiring caution when interpreting intraocular pressure values. There is no interchangeability between different tonometers.

Main examination methods

Gonioscopy and ultrasound biomicroscopy (UBM): Evaluation of residual iris tissue extent and angle abnormalities. Also useful for confirming anterior displacement of the ciliary body⁶⁾
Optical coherence tomography (OCT): Assesses glaucomatous thinning of the retinal nerve fiber layer. Macular OCT can also determine the degree of macular hypoplasia
Visual field testing: Difficult in children under 5 years, so kinetic perimetry is used. Perform regularly once the patient is old enough for accurate visual field assessment
Refraction and axial length measurement: Progression of myopia or axial elongation suggests glaucoma progression
Abdominal ultrasound: Screening for Wilms tumor. Perform regularly until age 6 in sporadic cases
Genetic testing: Detects mutations via PAX6 sequencing, MLPA, and CMA. Important for confirming WAGR syndrome²⁾

Differential diagnosis

Diseases that may be confused with aniridia are listed below¹⁾. These are disease groups that should be excluded as item C (differential diagnosis) of the diagnostic criteria.

Iris coloboma: Iris defect due to incomplete closure of the optic fissure, typically localized inferiorly. May be accompanied by choroidal coloboma. Distinguished from aniridia by the diffuse iris defect in aniridia
Axenfeld-Rieger anomaly: Characterized by iris adhesion to the posterior embryotoxon (anterior displacement and thickening of Schwalbe’s line), with pupillary deviation. Caused by PITX2/FOXC1 mutations, not PAX6 mutations
Traumatic or postoperative iris defect: Can be differentiated by history of trauma or surgery
Iris atrophy due to prior herpesvirus infection: Often unilateral; check for infection history and corneal hypoesthesia. Iris atrophy from herpes zoster or herpes simplex is often segmental
Iris-corneal endothelial (ICE) syndrome: Unilateral iris atrophy common in adult women. Presents with progressive corneal endothelial abnormalities leading to iris deformation and adhesions.

5. Standard Treatment

In aniridia with ocular hypertension or glaucoma, intraocular pressure management should be initiated early to preserve visual function ²⁾. Treatment is considered stepwise in the following order.

① Medication Therapy

First step: Lowering intraocular pressure with eye drops or oral medications

Medications used: Beta-blockers, carbonic anhydrase inhibitors (CAIs), prostaglandin analogs

② Outflow Reconstruction Surgery

Second step: When medication therapy is insufficient

Procedures: Goniotomy, trabeculotomy. The choice depends on the degree of angle abnormality.

③ Filtration Surgery/Tube

Third step: When outflow reconstruction is difficult or ineffective

Procedures: Trabeculectomy, long-tube surgery (Ahmed/Baerveldt)

④ Cyclophotocoagulation

Last resort: When all other treatments are ineffective

Caution: High risk of phthisis bulbi (loss of ocular function); ciliary body hypoplasia has been reported in aniridia.

Medication Therapy

Topical and oral intraocular pressure (IOP) control is the first-line treatment. In a long-term observation of 60 cases, glaucoma developed in 31 cases, and IOP was managed with medication alone in 12 of those cases³⁾.

The main medications used are as follows:

Beta-blockers (e.g., timolol): Caution for bradycardia and bronchospasm in children. Start with a low concentration.
Carbonic anhydrase inhibitors (CAIs): Topical (dorzolamide, brinzolamide) or systemic (oral acetazolamide).
Prostaglandin analogs (e.g., latanoprost): Effective, but may be less effective in children compared to adults.
Alpha-2 adrenergic agonists (brimonidine): Contraindicated in children under 2 years. Risk of severe neuropsychiatric symptoms such as coma²⁾⁷⁾.

In cases with limbal stem cell deficiency (LSCD) or risk of worsening LSCD, consider using preservative-free formulations⁷⁾.

Surgical Therapy

Outflow Reconstruction Surgery (Goniotomy/Trabeculotomy)

Goniotomy has been reported effective for controlling high IOP and glaucoma⁴⁾, and outflow reconstruction surgery should be considered as the initial procedure²⁾. Trabeculotomy has also been reported effective as an initial surgery⁵⁾. However, note the following:

In cases where residual iris tissue covers the trabecular meshwork, trabeculotomy may be ineffective.
Due to the absence of iris tissue, there is a risk of damaging the zonules of Zinn during trabeculotomy, which may affect lens development.
The degree of angle dysgenesis in aniridia varies greatly among individuals; surgical indication should be based on detailed angle evaluation using gonioscopy and UBM⁶⁾.

Trabeculectomy

This is selected when outflow reconstruction is difficult or unsuccessful. Although reports exist of achieving intraocular pressure control ¹¹⁾, the following issues remain.

Outcomes are generally poor in children, with postoperative phthisis bulbi reported in about 1/4 of cases ⁸⁾
There are reports of malignant glaucoma occurring after surgery
Use of antimetabolites (e.g., mitomycin C) should be carefully considered due to the risk of worsening AAK

Long-tube surgery (glaucoma implant surgery)

Baerveldt glaucoma implant and Ahmed glaucoma implant are available. This is selected when trabeculectomy is ineffective or when filtration surgery is expected to have poor outcomes due to angle pathology ²⁾.

A meta-analysis of Ahmed and Baerveldt implants for pediatric glaucoma (32 studies, 1221 eyes) showed a decrease in mean preoperative intraocular pressure from 31.8 mmHg to 16.5 mmHg (95% CI: 15.5–17.6) at 12 months. Success rates were 87% (95% CI: 0.83–0.91) at 12 months and 77% (95% CI: 0.71–0.83) at 24 months, but decreased to 37% (95% CI: 0.32–0.42) at 120 months ⁹⁾.

Arroyave et al. (2003) summarized the use of GDD for glaucoma associated with aniridia and reported a certain intraocular pressure-lowering effect ¹⁴⁾. Recent reviews also indicate that glaucoma drainage devices are a major option when outflow reconstruction or filtration surgery is insufficient ¹³⁾. In Japan, there are case reports of effective Baerveldt implant use ¹²⁾. In aniridic eyes, due to the absence of the iris, it is recommended to insert the tube tangentially rather than toward the center of the cornea ⁷⁾. In phakic eyes, attention must be paid to contact not only with the corneal endothelium but also with the lens.

Cyclophotocoagulation

This is a last resort when all surgical treatments are unsuccessful ²⁾.

Cyclocryotherapy leads to phthisis bulbi in many cases, and cataract development is frequent, making postoperative visual function maintenance difficult
In aniridia, ciliary body hypoplasia has been confirmed by UBM ⁶⁾, and the risk of phthisis bulbi is higher compared to healthy eyes ⁸⁾
Select only when the utility is high despite the risk of complications such as phthisis bulbi that lead to poor visual prognosis

Other ophthalmic management

Photophobia: Options include sunglasses and soft contact lenses (SCL) with artificial iris ²⁾
Low vision care: Based on refractive correction, use visual aids such as magnifiers, low vision glasses, and magnifying reading devices ²⁾. Educational support through enlarged textbooks and consultation at special needs schools for visual impairment is also important.
Cataract surgery: Develops in 50–85% of patients by age 20. The risk of intraoperative complications is high due to fragile zonules of Zinn. Postoperative glaucoma exacerbation and anterior fibrosis syndrome also require attention ²⁾.
Corneal stromal opacity: Full-thickness corneal transplantation has a high rate of rejection, and long-term visual prognosis is often poor due to glaucoma and graft failure ²⁾. For severe corneal stromal opacity, corneal transplantation combined with limbal transplantation or Boston keratoprosthesis may be considered.

Long-term intraocular pressure management and follow-up

In the management of glaucoma associated with aniridia, lifelong regular intraocular pressure monitoring is essential. Follow-up should be conducted with attention to the following points.

Childhood: In infants, note that even eye drops may result in a high dose relative to body weight and body surface area; use the lowest possible concentration of medication. Intraocular pressure measurement under general anesthesia may be necessary.
School age to adolescence: This is a period when glaucoma tends to become progressively apparent; once visual field testing becomes possible, regularly assess for glaucomatous visual field defects.
After surgery: Meta-analysis of tube shunt surgery shows a success rate of 87% at 12 months, decreasing to 37% at 120 months ⁹⁾, so the need for additional surgery in the long term should be kept in mind.
Multidisciplinary collaboration: Collaboration with pediatrics (Wilms tumor screening), genetics (genetic counseling), and educational support (low vision classes, special needs schools for visual impairment) is important. Many patients can attend regular classes but require support such as enlarged textbooks.

Q If glaucoma surgery becomes necessary, which surgical technique is chosen?

First, medication therapy is attempted; if insufficient, outflow reconstruction procedures such as goniotomy or trabeculotomy are considered. If these are difficult or ineffective, trabeculectomy is performed, followed by long-tube surgery (Ahmed or Baerveldt implant). Only when intraocular pressure control cannot be achieved with any treatment is cyclophotocoagulation considered as a last resort ²⁾.

Q Can glaucoma eye drops worsen the cornea?

Aniridia may be complicated by aniridia-associated keratopathy (AAK). Long-term use of eye drops containing preservatives (such as benzalkonium chloride) can worsen corneal epithelial damage, so the use of preservative-free formulations is recommended ⁷⁾.

6. Pathophysiology and Detailed Mechanisms

PAX6 Gene and Ocular Development

PAX6 encodes a transcription factor that regulates gene expression and is a master control gene expressed from the early eye. It is involved in optic cup formation, lens differentiation, and development of the corneal epithelium and retina. PAX6 haploinsufficiency affects not only the iris but also the macula, corneal limbal stem cells, optic nerve, and the entire eye.

PAX6 is also expressed in the central nervous system, pancreatic islets of Langerhans, and olfactory epithelium, and hypoplasia of these tissues leads to various extraocular complications ¹⁾.

Angle Dysgenesis and Glaucoma Pathogenesis

Pathologically, smooth muscle is absent except at the iris root, and angle development is incomplete. The pathogenesis of glaucoma progresses in stages as follows ³⁾.

Congenital angle dysgenesis due to PAX6 mutation
Remaining iris stroma (iris root tissue) extends anteriorly over the trabecular meshwork
Gradual covering of the trabecular meshwork, obstructing aqueous outflow
Elevated intraocular pressure → glaucomatous optic neuropathy

This progressive angle change was reported by Grant and Walton in 1974 ³⁾, and in recent years has been confirmed by UBM as anterior displacement of the ciliary body ⁶⁾. Depending on the degree of angle dysgenesis, both open-angle and closed-angle types can occur.

Pathophysiology of Aniridia-Associated Keratopathy (AAK)

PAX6 mutations also affect corneal limbal stem cells, leading to dysfunction of corneal epithelial stem cells.

Dysfunction of corneal epithelial stromal cells → Bowman’s layer abnormalities
Formation of vascularized pannus (invasion of conjunctival tissue into the cornea)
Progressive corneal opacity → decreased visual acuity

AAK often develops and progresses with growth even if normal in early childhood¹⁾. There are two types of keratopathy: congenital central corneal opacity (CCO) and AAK, and it has been reported that the rate of glaucoma complications is higher in cases with CCO than in those with AAK¹⁶⁾. Antimetabolites and preservative-containing eye drops used in glaucoma treatment carry a risk of worsening AAK, influencing treatment strategy selection. Since corneal and glaucoma management interact, an integrated evaluation of both is required.

Ciliary body hypoplasia

As an anatomical finding specific to aniridia, ciliary body hypoplasia has been reported on UBM⁶⁾. This finding is a factor that increases the risk of eyeball perforation during cyclophotocoagulation and also suggests that the amount of aqueous humor produced by the ciliary body may be lower than normal.

7. Latest research and future prospects (research-stage reports)

Prophylactic goniotomy

Chen and Walton (1999) reported that based on the natural course of progressive angle changes in aniridia, performing prophylactic goniotomy before the onset of ocular hypertension or glaucoma may prevent the development of glaucoma⁴⁾. However, this is a descriptive study without a control group, and the evidence is limited²⁾.

Future prospective studies are awaited regarding the efficacy of prophylactic surgical intervention.

Corneal reconstruction using stem cell transplantation

For the treatment of corneal epithelial stem cell deficiency (AAK), allogeneic limbal transplantation and cultured oral mucosal epithelial transplantation are being considered. In some cases, surgical treatment aims to reconstruct the ocular surface ²⁾. When corneal stromal opacity is present, combining corneal transplantation may be useful.

Genotype-phenotype correlation studies

Large-scale registry studies are elucidating the genetic profile of childhood and early-onset glaucoma ¹⁰⁾. Correlation analysis between PAX6 mutation types (e.g., PTC type, missense type) and glaucoma risk/severity is expected to lead to personalized medicine based on risk stratification.

8. References

大家義則, 川崎諭, 西田希ほか. 無虹彩症の診断基準および重症度分類. 日眼会誌 124:83-88, 2020.
厚生労働科学研究費補助金難治性疾患政策研究事業「角膜難病の標準的診断法および治療法の確立を目指した調査研究」研究班. 無虹彩症の診療ガイドライン. 日眼会誌 125:38-88, 2021.
Grant WM, Walton DS. Progressive changes in the angle in congenital aniridia, with development of glaucoma. American journal of ophthalmology. 1974;78(5):842-7. doi:10.1016/0002-9394(74)90308-0. PMID:4423758.
Chen TC, Walton DS. Goniosurgery for prevention of aniridic glaucoma. Archives of ophthalmology (Chicago, Ill. : 1960). 1999;117(9):1144-8. doi:10.1001/archopht.117.9.1144. PMID:10496385.
Adachi M, Dickens CJ, Hetherington J Jr, Hoskins HD, Iwach AG, Wong PC, et al. Clinical experience of trabeculotomy for the surgical treatment of aniridic glaucoma. Ophthalmology. 1997;104(12):2121-5. doi:10.1016/s0161-6420(97)30041-4. PMID:9400774.
Okamoto F, Nakano S, Okamoto C, et al. Ultrasound biomicroscopic findings in aniridia. Am J Ophthalmol 137:858-862, 2004. doi:10.1016/j.ajo.2003.12.014.
Khaw PT. Aniridia. J Glaucoma 11:164-168, 2002.
Jain A, Gupta S, James MK, Dutta P, Gupta V. Aniridic Glaucoma: Long-term Visual Outcomes and Phenotypic Associations. Journal of glaucoma. 2015;24(7):539-42. doi:10.1097/IJG.0000000000000019. PMID:24618569.
Stallworth JY, O’Brien KS, Han Y, Oatts JT. Efficacy of Ahmed and Baerveldt glaucoma drainage device implantation in the pediatric population: a systematic review and meta-analysis. Surv Ophthalmol. 2023;68(4):578-590. doi:10.1016/j.survophthal.2023.01.010. PMID:36740196; PMCID:PMC10293048.
Knight LSW, Ruddle JB, Taranath DA, Goldberg I, Smith JEH, Gole G, Chiang MY, Willett F, et al. Childhood and Early Onset Glaucoma Classification and Genetic Profile in a Large Australasian Disease Registry. Ophthalmology. 2021;128(11):1549-1560. doi:10.1016/j.ophtha.2021.04.016. PMID:33892047.
Wiggins RE Jr, Tomey KF. The results of glaucoma surgery in aniridia. Arch Ophthalmol 110:503-505, 1992. doi:10.1001/archopht.1992.01080160081036.
山田香奈子, 上松聖典, 藤川亜月茶ほか. 先天無虹彩に伴う緑内障に対しバルベルト緑内障インプラントが有効であった1例. 臨眼 71:389-394, 2017.
Muñoz-Negrete FJ, Teus MA, García-Feijoó J, Canut MI, Rebolleda G. Aniridic glaucoma: an update. Arch Soc Esp Oftalmol (Engl Ed). 2021;96 Suppl 1:52-59. PMID: 34836589. doi:10.1016/j.oftale.2020.11.011.
Arroyave CP, Scott IU, Gedde SJ, Parrish RK 2nd, Feuer WJ. Use of glaucoma drainage devices in the management of glaucoma associated with aniridia. American journal of ophthalmology. 2003;135(2):155-9. doi:10.1016/s0002-9394(02)01934-7. PMID:12566018.
Chang JW, Kim JH, Kim SJ, Yu YS. Congenital aniridia: long-term clinical course, visual outcome, and prognostic factors. Korean journal of ophthalmology : KJO. 2014;28(6):479-85. doi:10.3341/kjo.2014.28.6.479. PMID:25435751; PMCID:PMC4239467.
Gramer E, Reiter C, Gramer G. Glaucoma and frequency of ocular and general diseases in 30 patients with aniridia: a clinical study. European journal of ophthalmology. 2012;22(1):104-10. doi:10.5301/EJO.2011.8318. PMID:22167549.

Related keywords